SeaCrest Wealth Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

SeaCrest Wealth Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200	Closed	-$3K	–	2074
2019 Q1	$3K	Hold	200	–	–	﹤0.01%	1886
2018 Q4	$2K	Hold	200	–	–	﹤0.01%	1951
2018 Q3	$3K	Hold	200	–	–	﹤0.01%	2021
2018 Q2	$3K	Hold	200	–	–	﹤0.01%	1963
2018 Q1	$3K	Hold	200	–	–	﹤0.01%	1940
2017 Q4	$4K	Buy	+200	New	+$6.43K	﹤0.01%	1890

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SeaCrest Wealth Management's FPRX Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2019, closing a stake of 200 shares — an estimated $3K sold.

SeaCrest Wealth Management first reported a position in FPRX in Q4 2017 and held it in 6 quarters. The position peaked at $4K in Q4 2017. 114 funds tracked by Wall St. Rank hold FPRX as of Q2 2019.

SeaCrest Wealth Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 200 Five Prime Therapeutics, Inc. shares in Q2 2019, an estimated $3K.
SeaCrest Wealth Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's Five Prime Therapeutics, Inc. position peaked at $4K in Q4 2017.
114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.